All In Biotech

NDA 020983 · Glaxosmithkline

Ventolin Hfa

Albuterol Sulfate · Inhalation

Last checked: Nov 19, 2026Latest source record: Aug 18, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Apr 19, 2001

Approved uses

2

Original approval plus efficacy supplements

Registered trials

793

238 Phase 3, 24 recruiting

FAERS reports

185,312

93,948 serious, 9,526 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 24, 2026.

VENTOLIN HFA is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airway disease. ( 1.1 ) Prevention of exercise-induced bronchospasm in adult and pediatric patients aged 4 years and older. ( 1.2 ) 1.1 Bronchospasm VENTOLIN HFA is indicated for the treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airway disease. 1.2 Exercise-Induced Bronchospasm VENTOLIN HFA is indicated for the prevention of exercise-induced bronchospasm in adult and pediatric patients aged 4 years and older.

Mechanism: In vitro studies and in vivo pharmacologic studies have demonstrated that albuterol has a preferential effect on beta 2 -adrenergic receptors compared with isoproterenol. Although beta 2 -adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -adrenoceptors are the predominant receptors in the heart, there are also beta 2 -adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta 2 -agonists may...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 26, 2008 Supplement 16 · Efficacy · priority review LabelLetter
  • Apr 19, 2001 Original approval · Type 3 - New Dosage Form LetterLabelReview
1 products under this application
  • VENTOLIN HFA · ALBUTEROL SULFATE EQ 0.09MG BASE/INH · AEROSOL, METERED, INHALATION · Prescription · TE AB3

Clinical trials

Interventional ClinicalTrials.gov studies with "Albuterol" as an intervention, any sponsor and status, largest first.

All 793 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea28,605
  • wrong technique in product usage process18,262
  • asthma17,594
  • cough13,988
  • drug ineffective13,804
  • fatigue10,845
  • pneumonia10,641
  • headache10,172
  • wheezing9,464
  • no adverse event8,917
  • off label use8,314
  • nausea8,304

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004691
2005683
2006535
2007558
20081,012
20091,163
20101,557
20112,314
20122,733
20132,937
20145,379
20158,729
201610,712
201710,791
201811,375
201912,933
202014,530
202114,317
202213,878
202316,402
202419,195
202518,830
202614,056

Recalls

5 FDA enforcement reports for this application.

  • Jan 26, 2022 · Class II · Terminated

    CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

  • May 16, 2017 · Class II · Ongoing

    Defective Delivery System: Elevated number of units with out of specification results for leak rate

  • Mar 22, 2017 · Class II · Ongoing

    Defective Delivery System: Elevated number of units with out of specification results for leak rate.

  • Dec 3, 2015 · Class II · Terminated

    Defective Delivery System: Some canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf life.

  • Jul 26, 2012 · Class II · Terminated

    Does Not Deliver Proper Metered Dose: Potential content of albuterol per dose is below specification.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ventolin HFA (Albuterol Sulfate)

2024 spending

$153M

Beneficiaries

850,779

2,272,575 claims

Per beneficiary

$180

$3.05 per unit

View as table
YearSpending
2020$314,326,928
2021$195,533,210
2022$170,323,373
2023$192,500,838
2024$152,856,347

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 987 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.